Latest Biologicals News

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.

New Zealand King Salmon reported an FY25 net loss driven by a shortened reporting period and biological challenges, while advancing its Blue Endeavour pilot project despite delays. The company projects a cautious recovery in FY26 with EBITDA guidance between NZD 9 million and 15 million.

New Zealand King Salmon reports a $6.3 million net loss for an eight-month FY25 period, reflecting operational challenges and a shortened reporting cycle, while outlining cautious optimism for FY26 with targeted growth investments.

Patrys Limited has expanded its clinical pipeline by acquiring Reliis Pty Ltd, gaining a proprietary injectable formulation of Quetiapine aimed at the large and underserved delirium market. This strategic move balances Patrys’ portfolio with a near-term pharmaceutical asset alongside its biologics program.

Syntara Limited has successfully completed Phase 1a trials for its topical anti-fibrotic drug SNT-9465, demonstrating dose-dependent target engagement and safety, and is now progressing to an innovative Phase 1b study in hypertrophic scars.

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.

Mesoblast has achieved a landmark FDA approval for RYONCIL, the first allogeneic mesenchymal stromal cell therapy, driving strong commercial momentum and advancing a robust pipeline targeting inflammatory diseases.

Island Pharmaceuticals has secured membership in the Medical Countermeasures Coalition, positioning its antiviral Galidesivir for critical US government stockpiling and regulatory milestones.

Bio-Gene Technology reports significant progress in developing its bio-insecticides Flavocide and Qcide, including new efficacy data and organic certification, positioning the company for growth amid rising global demand for safer pest control.

Terragen Holdings has secured a major purchase order from Mort & Co Fertilisers for its Great Land Plus® bio-stimulant, projecting a significant sales boost in 2026. This deal underscores growing demand for sustainable agricultural solutions.

Algorae Pharmaceuticals has launched AlgoraeOS Version 2, a major AI platform upgrade that surpasses leading models including those from Google DeepMind, promising to accelerate drug-combination discovery.

Monash University has secured a $799,866 Australian Research Council grant to study brain injury thresholds using HITIQ’s PROTEQT™ instrumented mouthguards, with a $200,000 pre-order confirming commercial momentum.